Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?

Abstract

The current cancer testing gene panels tend to be comprehensive rather than site-specific. BARD1 is one of the genes commonly included in the multi-cancer testing panels. Mutations in BARD1 confer an increase in the risk for breast cancer, but it is not studied whether or not they predispose to prostate cancer. To establish if BARD1 mutations also predispose to prostate cancer, we screened BARD1 in 390 Polish patients with hereditary prostate cancer. No truncating mutations were identified by sequencing. We also genotyped 5715 men with unselected prostate cancer, and 10,252 controls for three recurrent BARD1 variants, including p.Q564X, p.R658C and p.R659=. Neither variant conferred elevated risk of prostate cancer (ORs between 0.84 and 1.15, p-values between 0.57 and 0.93) nor did they influence prostate cancer characteristics or survival. We conclude that men with a BARD1 mutation are not at elevated prostate cancer risk. It is not justified to inform men about increased prostate cancer risk in case of identification of a BARD1 mutation. However, a female relative of a man with a BARD1 mutation may benefit from this information and be tested for the mutation, because BARD1 is a breast cancer susceptibility gene.

Family history of cancer is associated with poorer prognosis in oral squamous cell carcinoma

“…Family history of cancer was determined by questioning the patient and/or family members at the time of initial diagnosis. FHC was considered positive if evidence existed for a malignant tumor in a first‐ or second‐degree relative consistent with other studies (Rogoza‐Janiszewska et al, 2020). First‐degree relatives (FDRs) included parents, siblings, and offspring while second‐degree relatives (SDRs) included aunts, uncles, nieces, nephews, and grandparents.…”